Explore the Agenda
8:00 am Check-in & Morning Coffee
8:50 am Chair’s Opening Remarks
Outlining the Development of Bispecifics & T-Cell Engagers in Autoimmune Diseases to Expand Their Therapeutics Application
9:00 am Exploring How Cis-Acting PD-1 Bispecific Antibodies Enable Tunable Checkpoint Modulation Through Immune Synapse Sequestration or Recruitment
- Outline the cis-acting PD-1 bispecific framework that enables programmable checkpoint modulation by controlling PD-1 spatial positioning at the immune synapse through defined molecular geometry
- Exploring how this design strategy supports both antagonist and agonist outcomes, linking synapse exclusion or recruitment of PD-1 to distinct signaling states and T-cell functional programs without Fc receptor dependence
- Discussing how this approach establishes a unified path from molecular design and epitope selection to disease-relevant immune modulation across oncology and autoimmune models
9:30 am Outlining ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation
- Discuss how ZW1528 high-affinity binding to IL-4Ra and IL-33 mediates potent blockade of IL-4, IL-13, and IL-33 pathways, and drives in vitro inhibition of type 2 and non-type 2 responses in primary immune cells of COPD patients
- Demonstrate that ZW1528 significantly reduces both systemic and local lung inflammation in mice with humanized IL-4/IL-4Ra
- Review ZW152’s good tolerability and favorable pharmacokinetics in the NHP and biomarkers of target blockade
- Unveil how these findings validate the rational design of ZW1528 and support its therapeutic potential across a range of airway inflammatory conditions
10:00 am Refreshment Break
10:30 am Networking Session
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your TPD candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, bispecifics and T-cell engagers, as well as global service providers through, in a mix of pre-organized and ad-hoc networking
11:30 am Designing Molecules to Decouple Potency From CRS in Autoimmune T-Cell Engagers
- Discover how Y108 is a PEGylated CD3/CD19 T-cell engager derived from the clinically validated blinatumomab platform
- Outline how, by leveraging established PEGylation technology, JY108 is designed to reduce cytokine release syndrome and improve tissue penetration
- Examine preclinical studies in autoimmune disease models that support its potential as a novel B-cell depletion therapy for autoimmune indications
12:00 pm Advancing Next-Generation Bispecific Antibodies: From Rigidity to Flexibility for Differentiation & Clinical Translation
- Designing the strategy and target rationale of FlexiBody®, a multi-specific antibody platform
- Engineering considerations to optimize efficacy while mitigating on-target toxicity
- Exploring translational insights supporting clinical development and differentiation
12:30 pm Lunch
1:30 pm Discussing NanoMabs as a Modular Platform for Next-Generation Bispecific & NanoMab-Drug Conjugates
- Defining the medical and technical unmet needs in bispecific antibodies and ADCs
- Addressing the unmet needs through NanoMab (nanobody-based) solutions
- Outlining the potential market impact and future implications of NanoMab-enabled therapeutics
2:00 pm Advancing First-in-Class & Best-in-Class Multispecific ADC & T-Cell Engager Therapies
- Leveraging proprietary target mining and drug discovery platforms to enable first-in-class (FIC) and best-in-class (BIC) multispecific biologic development
- Design and development strategy behind multispecific ADC and T-cell engager programs, including differentiation within competitive target landscapes
- Pipeline progression and strategic collaborations supporting clinical translation of multispecific platforms
2:30 pm Refreshment Break
3:00 pm Reshaping the Patient T-Cell Landscape: Overcoming T-Cell Engager Limitations Through Cytokine Combination Strategies
- Examining key limitations of current T-cell engager therapies, including T-cell exhaustion, suboptimal activation, and durability challenges in solid tumors, and where rational combination strategies are emerging as a solution
- Discussing the scientific rationale for combining T-cell engagers with immunocytokines to reshape the tumor microenvironment and enhance T-cell expansion, activation, and persistence
- Exploring translational and clinical development considerations for advancing cytokine + TCE combinations into phase 2 studies, including biomarker strategy and anticipated indicators of synergy
3:30 pm CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity
- CT-P72/ABP-102 bound specifically to human and cynomolgus macaque HER2 and CD3, and exhibited lower binding to both HER2 and CD3 compared to its parental antibody ABP 10.0
- CT-P72/ABP-102 demonstrated activity in T-cell activation, PBMC-mediated cytotoxicity, and cytokine release experiments comparable to the parental bispecific antibody with HER2 high-expressing tumor target cells but exhibited reduced activity with HER2-low tumor target cells
- CT-P72/ABP-102 was well tolerated, with the NOAEL determined to be 80 mg/kg when administered twice a week for 4 weeks (total of 8 doses).
4:00 pm T-Sphaera: A Next-Generation Biopharmaceutical Development Platform Enabling Advanced Multispecific Therapeutics
- Explore how T-Sphaera is a proprietary development platform designed to enable the rational engineering of next-generation multispecific biologics with enhanced stability, manufacturability, and functional precision
- Discuss how the platform supports flexible modular design, allowing optimization of target engagement, conditional activation, and therapeutic index across diverse oncology applications
- Examine how T-Sphaera-derived candidates were shown to improve tumor selectivity and translational predictability, supporting advancement toward clinical development